OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with ...
Please provide your email address to receive an email when new articles are posted on . Researchers compared the 21-valent vaccine to a combination of a 15-valent and 23-valent vaccines. Fewer adverse ...
Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027 OPUS-1, VAX-31 ...
—Spanish investigators analyzed pneumococcal lineages among adults with invasive pneumococcal disease (IPD) and assessed how the emergence of nonvaccine serotypes has contributed to the burden of ...
Without the backstop of mandates, vaccine products face a steep uphill climb to penetrate clinical conversations. Here's what ...
Researchers at BITS Pilani Hyderabad Campus develop experimental vaccine against Streptococcus pneumoniae, offering hope for ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company could go up against ...
"Reflecting on the Dutch Health Council's decision in 2018 to choose PPV23 for pneumococcal vaccination in older adults, our results on [vaccine effectiveness] against IPD align with the anticipated ...
Health and Me on MSN
Former AIIMS director Dr Randeep Guleria explains essential vaccinations every adult should take
​According to the World Health Organization (WHO), immunization currently prevents 3.5 million to 5 million deaths every year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results